HRPC(SH:600829)2018-10-22 16:00Financial Performance - Net profit attributable to shareholders decreased by 2.94% to CNY 202,048,231.35 for the reporting period [7]. - Operating revenue for the first nine months was CNY 5,346,024,697.83, a decline of 14.30% year-on-year [6]. - Basic earnings per share decreased by 2.95% to CNY 0.3484 [7]. - The weighted average return on net assets decreased by 0.06 percentage points to 12.89% [7]. - Total operating revenue for Q3 2018 was 1,888,732,470, a decrease of 15.5% from 2,235,518,977 in Q3 2017 [30]. - Net profit for Q3 2018 was 67,833,431, a decrease of 1.8% compared to 69,060,836 in Q3 2017 [32]. - The company recorded a total operating profit of ¥3,419,277.41 for the first nine months, compared to ¥5,498,818.8 in the previous year, reflecting a decline of about 38% [36]. Cash Flow - Net cash flow from operating activities was CNY 143,406,954.84, a significant recovery from a negative cash flow of CNY -25,647,303.84 in the same period last year [6]. - Cash flow from operating activities generated a net amount of ¥143,406,954.84, a turnaround from a negative cash flow of -¥25,647,303.84 in the same period last year [40]. - The net cash flow from operating activities was 18,192,647.83 CNY, a significant improvement from -8,769,283.72 CNY in the same period last year [44]. - The cash inflow from operating activities was 43,388,516.52 CNY, a substantial increase from 12,081,552.62 CNY year-over-year, reflecting a growth of approximately 259.5% [44]. Assets and Liabilities - Total assets decreased by 13.71% to CNY 4,177,818,476.53 compared to the end of the previous year [6]. - Current liabilities decreased from CNY 3,077,947,462.89 to CNY 2,506,614,062.13, a reduction of about 18.5% [23]. - Total liabilities decreased from CNY 3,229,369,249.72 to CNY 2,653,686,182.35, representing a decrease of approximately 17.8% [24]. - Owner's equity decreased from CNY 1,612,028,394.11 to CNY 1,524,132,294.18, a decline of about 5.4% [24]. - The company’s total current assets decreased to ¥3,676,596,859.59 from ¥4,317,503,183.59 at the beginning of the year [22]. Shareholder Information - The total number of shareholders reached 19,069 by the end of the reporting period [11]. - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holds 74.82% of the shares [11]. - The company’s major shareholder, Hainan Haiyao Investment Co., Ltd., pledged 25,428,300 shares, representing 4.39% of the total share capital [16]. - Hainan Sailamin Biotechnology Co., Ltd. reduced its shareholding from 5.05% to 4.9999% after selling 260,800 shares [17]. Government and Non-Operating Income - Government subsidies recognized during the reporting period amounted to CNY 5,225,091.17 [9]. - Non-operating income and expenses resulted in a net loss of CNY -1,169,126.67 for the reporting period [10]. Inventory and Receivables - Accounts receivable increased by 52.25% to ¥171,595,285.70 due to higher acceptance bill collections compared to the beginning of the year [14]. - Inventory decreased by 43.73% to ¥528,054,228.77 primarily due to sales of winter stock from the previous year [14]. - Other receivables decreased from CNY 252,803,063.87 to CNY 63,759,139.91, a decline of about 74.8% [26]. Expenses - Financial expenses increased by 52.12% to ¥16,658,158.34 mainly due to an increase in discount interest [15]. - The company incurred sales expenses of 61,847,134.6 in Q3 2018, up from 59,665,391.51 in Q3 2017 [30]. - Management expenses for Q3 2018 were 70,982,600.3, a decrease from 76,623,649.33 in Q3 2017 [30]. - Research and development expenses totaled ¥3,878,680.90 for the first nine months, compared to ¥4,180,776.21 in the previous year, showing a reduction of approximately 7% [35].